In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

MUM and daughter Gill Foster and Ellie Westcott have a combined 50 years of dieting between them. But the pair say that none ...

Weight loss can reverse the cardiovascular changes that take place in the heart, but will a new diet and exercise work, or is ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

The drug is set to be available on the NHS for weight loss soon, but one expert has flagged some potential risks that come with it.

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

Doctor Mark Porter revealed the potential side effects of the jab, which is set to be prescribed for weight loss on the NHS ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...